The effect of high glucose on the inhibitory action of C21, a selective AT2R agonist, of LPS-stimulated tissue factor expression in human mononuclear cells

Cristina Balia, Valentina Scalise, Silvana Cianchetti, Francesca Faita, Tommaso Neri, Vittoria Carnicelli, Riccardo Zucchi, Alessandro Celi and Roberto Pedrinelli*

Abstract

Background: Intimate links connect tissue factor (TF), the principal initiator of the clotting cascade, to inflammation, a cross-talk amplified by locally generated Angiotensin (AT) II, the effector arm of the Renin Angiotensin System (RAS). C21, a selective AT2R agonist, downregulates the transcriptional expression of TF in LPS-activated peripheral blood mononuclear cell (PBMC) s implying the existence of ATII type 2 receptor (AT2R)s whose stimulation attenuates inflammation-mediated procoagulant responses. High glucose, by activating key signalling pathways and increasing the cellular content of RAS components, augments TF expression and potentiates the inhibitory effect of AT1R antagonists. It is unknown, however, the impact of that stimulus on AT2R-mediated TF inhibition, an information useful to understand more precisely the role of that signal transduction pathway in the inflammation-mediated coagulation process. TF antigen (ELISA), procoagulant activity (PCA, 1-stage clotting assay) and TF-mRNA (real-time polymerase chain reaction) were assessed in PBMCs activated by LPS, a pro-inflammatory and procoagulant stimulus, exposed to either normal (N) or HG concentrations (5.5 and 50 mM respectively).

Results: HG upregulated TF expression, an effect abolished by BAY 11-7082, a NFκB inhibitor. C21 inhibited LPS-stimulated PCA, TFAg and mRNA to an extent independent of glucose concentration but the response to Olmesartan, an AT1R antagonist, was quite evidently potentiated by HG.

Conclusions: HG stimulates LPS-induced TF expression through mechanisms completely dependent upon NFkB activation. Both AT2R-stimulation and AT1R-blockade downregulate inflammation-mediated procoagulant response in PBMCs but HG impacts differently on the two different signal transduction pathways.

Keywords: Tissue factor, Thrombosis, Renin angiotensin system, Innate immunity endotoxin, Inflammation, Renin angiotensin blockers
antagonists downregulate activated TF expression [12, 13] among others) but the inhibitory effect of selective AT2R stimulation [14] is suggestive of the existence of AT2Rs counteracting the AT1R-mediated procoagulant phenotype, as reported for other AT2R-mediated functions [15].

High glucose (HG) concentrations, by accelerating reactive oxygen species (ROS) generation and increasing NFkB-induced cytokine production e.g. [16–18], increase TF expression in human peripheral blood mononuclear cells (PBMCs), amplify procoagulant responses in cells activated by endotoxin (Lipopolysaccharide, LPS) and potentiate the inhibitory action of RAS blockers including AT1R antagonists [13]. However, the influence of high glucose environment, an experimental condition reproducing, to some extent, the diabetic state hallmark, on the TF modulation induced by AT2R agonism is unknown, a piece of evidence useful to understand in more detail the role of the AT2R signal transduction pathway in the inflammation-mediated coagulation process.

For this reason, we investigated the effect of C21, a recently synthesized selective AT2R agonist [19], on TF expression in human PBMCs exposed to HG and activated by lipopolysaccharide (LPS, endotoxin), a well characterized target of the innate immune system [20] and a procoagulant agent [2]. Olmesartan (OLM), a selective AT1R antagonist [21], was used as a control.

**Methods**

**Cell isolation and culture**

Human PBMCs were obtained from unpooled buffy coats left over from blood bank draws taken from healthy donors with the approval of the local ethics committee. According to local procedures, individuals with a history of diabetes and hypertension, either on antihypertensive drugs or not, are excluded from blood donation. As detailed elsewhere [22], leukocytes were isolated from fresh buffy coats diluted 1:1 with sodium citrate 0.38 % in saline solution, mixed gently with 0.5 volume of 2 % Dextran T500 and left for 40 min for erythrocyte sedimentation. The leukocyte-rich supernatant was recovered and centrifuged for 10 min at 200xg. The pellet was resuspended in 30 ml of sodium citrate solution, layered over 15 ml of Ficoll-Hypaque and centrifuged for 30 min at 350xg at 20 °C. The PBMC-rich ring was recovered, washed twice in sodium citrate 0.38 % and resuspended in no glucose RPMI 1640 medium (Sigma Chemical, St Louis, Missouri, USA) supplemented with 100 U/ml penicillin-streptomycin. The final PBMC preparations typically contain 25–35 % monocytes, 65–75 % lymphocytes and less than 5 % neutrophils [22].

After isolation, cells resuspended in polypropylene tubes (3x10⁶ cells/ml) were exposed to experimental drugs or their appropriate vehicle in presence of two different D-glucose concentrations (5.5 mM, hereafter referred to as Normal Glucose, NG, or 50 mM heretofore referred to as High Glucose, HG) 30 min prior to LPS (Escherichia coli 026:B6 LPS; Sigma Chemical), 100 ng/ml, and left to incubate for 18 hs at 37 °C in a 5 % CO₂ atmosphere until assay. Previous experiments had shown the D-glucose concentration-dependent increase in TF procoagulant activity (see below) as well as the neutral effect of L-Glucose used as a control for osmolarity changes [13] and, therefore, were not repeated. Untreated PBMCs were also included in each experimental series to obtain baseline values. All reagents and solutions used for cell isolation and culture were prepared with endotoxin-free water and glassware was rendered endotoxin-free by exposure to high temperature. Drugs were kept in stock solution and diluted in serum-free RPMI at the appropriate concentrations immediately before use. Cell viability as assessed by dimethyl thiazolyl diphenyl tetrazolium (MTT) was verified (85 % or more of viable cells) throughout all experimental phases.

**Experimental methods**

**TF procoagulant activity (PCA)**

PCA was assessed by a one-stage clotting time test in PBMCs disrupted by three freeze–thaw cycles, as previously described [23]. In brief, disrupted cells (100 µl) were mixed with 100 µl of normal human plasma at 37 °C, adding 100 µl of 25 mmol/l CaCl₂ at 37 °C. Time to clot formation was recorded and values converted to arbitrary units (AU) by comparison with a human brain TF calibration curve covering clotting times from 20 to 600 s, corresponding to 1000 and 0 AU, respectively. Experiments were run in triplicate and averaged. As contaminating platelets may contribute to PCA [24], we performed the clotting assay in PBMC-free preparations in which PCA was undetectable (data not shown). Preliminary experiments had also confirmed the procoagulant effect of ATII (10⁻⁶M) added to PBMCs exposed to either NG (from 0.005 ± 0.002 to 0.01 ± 0.006 AU, n = 14, p < 0.01) or HG (from 0.011 ± 0.007 to 0.02 ± 0.01 AU, n = 10, p < 0.05).

**TF antigen (Ag)**

Cells were disrupted by three repeated freeze–thaw cycles and debris pelleted by centrifugation at 100xg for 1 h at 4 °C and supernatants used for ELISA (Imubind TF kit Sekisui Diagnostics, West Malling, United Kingdom). TF Ag levels were expressed in pg/ml using a reference curve created by the TF standards. Within and between assay variability was 3.5 and 5.5 %, respectively.

**TF mRNA**

Total RNA was extracted from PBMCs using the RNeasy mini kit (Qiagen, Hilden, Germany). RNA concentration and purity were determined by optical density measurement
via Nanodrop (Thermo Fisher Scientific, Wilmington, Delaware USA). A mixture of 0.5 ng total RNA per sample was retro-transcribed with random primer-oligodT into complementary DNA (cDNA) using the Quantitect Reverse Transcription Kit (Qiagen, Hilden, Germany). The retro-transcription cycle was performed at 25 °C for 5 min, 42 °C for 30 min and 95 °C for 3 min. RealTime-PCR was carried out in a iQ5 Real Time PCR System and SsoAdvanced Sybr Green Supermix (Bio-Rad Laboratories, Hercules, CA) was employed on the basis of the manufacturer’s conditions: 95 °C, 30s; 40 cycles 95 °C, 5 s, 60 °C, 15 sa final melting protocol with ramping from 65 °C to 95 °C with 0,5 °C increments of 5 s was performed. The primers sequence for RealTime-PCR were: TF, sense 5'-TTGGCAAGGACTTATATTATACAC-3', antisense 5'-CTGTTCCGGAGGGAATCAC-3'; GAPDH, sense: 5'-CCCTTCATTGCCCTCACTCATAGTATTCCATGATGCAAGC-3' and antisense: 5'-TGGGATTTCCATTGATGACAAGC-3' (Invitrogen, Monza, Italy). All samples were analysed in duplicate and averaged. The relative expression of the target gene was normalized to the level of GAPDH in the same cDNA.

**Experimental design**

**Effect of HG**

TF PCA, Ag and mRNA were assessed in resting and LPS-stimulated PBMCs exposed to either NG or HG. To evaluate the involvement of NF-kB in that setting, TF PCA was assessed in LPS-stimulated PBMCs exposed to either NG or HG and pretreated with BAY 11-7082 (10^-5 M Sigma, Milan, Italy), a NF-kB inhibitor [25], or not.

**Effect of AT2R agonism by C21 and AT1R blockade by OLM**

Either C21, a selective AT2R agonist [19], or OLM, a selective AT1R antagonist [20], were added at log-increasing steps (10^-8, 10^-5 M for both) to LPS-activated PBMCs incubated in either NG or HG media.

**Effect of AT2R antagonism**

To confirm its AT2R selectivity, C21 was added at log-increasing steps (10^-8, 10^-5 M) to LPS-activated PBMCs incubated in NG or HG media in absence or presence of PD123,319 (10^-6 M, di(trifluoroacetate) salt hydrate, Sigma Milan, Italy), a selective AT2R antagonist [26].

**Statistics**

Statistical differences were assessed by non parametric tests (Wilkoxon’s and Mann-Whitney for paired and unpaired comparisons respectively) on either absolute data or percent changes from control conditions, these latter taken as a measure of drug effect. Data were reported as means ± SD unless otherwise reported. A two-tailed p-level <0.05 was the threshold for statistical significance.

### Results

**Effect of HG on TF expression**

Resting and LPS-stimulated TF PCA, Ag and mRNA were greater in HG than NG (Table 1). In both experimental conditions, BAY 11-7082 (10^-5 M) abolished LPS-stimulated PCA (Fig. 1).

**Effect of HG on C21 and OLM**

Both C21 and OLM downregulated LPS-induced TF PCA (Fig. 2). However, the extent of inhibition exerted by C21 was by and large not influenced by D-glucose concentrations (Fig. 2, left panel) in contrast with OLM whose effect was potentiated in HG (Fig. 2, right panel).

A similar behaviour was found when analyzing the effect of the two drugs on TFAg and TFmRNA (Fig. 3, left and right panel respectively).

**Effect of AT2R antagonism**

PD123,319 (10^-6 M) abolished the effect of C21 in both NG and HG (Fig. 4, left and right panel respectively).

### Discussion

**Background of the study**

The interpretation of the results of this study are facilitated by some further discussion of the involvement of ATII in innate immunity, a biological system by which germline-encoded receptor proteins recognize specific patterns presented by groups of pathogens [20]. Among them, LPS, the proinflammatory stimulus used in our experimental series, constitutes a major marker for the recognition of intruding Gram-negative bacteria that, by binding to Toll-like receptor(TLR)4 s and CD14 and recruiting adaptor proteins to the cytoplasmic Toll/interleukin-1 receptor, initiates the pathogen-induced inflammatory response of which activation of coagulation is a prominent component [1, 20]. ATII contributes to the

| Table 1 | Resting and LPS(100 ng/ml)-stimulated Tissue Factor (TF) procoagulant activity (PCA), antigen(ag) and mRNA in normal (NG, 5.5 mM) and high (HG, 50.0 mM) glucose conditions |
|---------|--------------------------------------------------|
| TF PCA (AU) | NG | HG |
| Resting | 0.0054 ± 0.003 | 0.035 ± 0.4* |
| LPS-stimulated (N = 33) | 0.93 ± 0.36** | 2.7 ± 1.1*, ** |
| TFAg (ng/mL) | | |
| Resting | 32 ± 24 | 428 ± 135* |
| LPS-stimulated (N = 12) | 1486 ± 388*** | 2652 ± 622*, ** |
| TF mRNA (normalized fold expression) | | |
| Resting | 0.007 ± 0.003 | 0.158 ± 0.1* |
| LPS-stimulated (N = 8) | 0.65 ± 0.5** | 0.85 ± 0.5*, ** |

*p < 0.001 HG vs NG, **p < 0.001 LPS- stimulated vs resting
 innate immune response through complex and interrelated transcriptional and posttranscriptional mechanisms including upregulation of the TLR4 expression leading to a more intense NF-κB activation e.g. [27–29]. In turn, LPS or its intracellular proxies such as TNF-alpha [20] stimulate ATII generation [30] by activating renin, the earlier step of its biosynthetic chain [31], and increasing the number of ATII receptors available for stimulation by the peptide [32]. Thus, immunomodulation appears as an integral component of RAS functions far away from the conventional view of a hormonal system mainly involved in systemic blood pressure and body fluid volume control.

Although primarily aimed at the acute defence against infection and tissue damage, a growing body of evidence implicates innate immunity in several chronic conditions including type 2 diabetes [33] in which raised glucose concentrations, the hallmark of that disease, induce overexpression of Toll-like receptor (TLR) [34, 35] and CD14 [36], promote de-novo local synthesis of RAS components [37, 38] and potentiate a wide array of ATII-mediated biological actions e.g. [39–41]. By stimulating NADPH oxidase and mitochondrial metabolism, HG also accelerates reactive oxygen species (ROS) generation activating NFκB [16–18], thus initiating TF gene transcription along with a host of other proinflammatory cytokines. That concept is fully in line with our results showing upregulation by HG of both quiescent and LPS-induced TF PCA, mRNA and Ag expression and abolition of activated PCA by BAY11-7082, a NF-κB inhibitor [25], demonstrates the complete dependency upon the NFκB signalling pathway of the procoagulant effect of endotoxin in human PBMCs.

**HG and AT2R agonism on LPS-stimulated TF expression**

Within the frame of reference summarized in the previous paragraph, our data confirm the inhibitory action of AT2R agonism by C21 on LPS-stimulated TF expression in human PBMCs [14] and the complete antagonism exerted by PD123,319 reassures about the specificity of the response. The parallel decrease of TF Ag and mRNA is consonant with transcriptional modulation of TF protein likely by NFκB downregulation [41], an interpretation fully supported by recent reports showing attenuated cytokine production by C21 in LPS-stimulated mononuclear cells.
In addition to those relevant albeit confirmatory findings, however, the main and original pathophysiological implications of this study arise from the contrast between the neutral effect of HG on C21-induced TF inhibition and the potentiated effect of AT1R blockade by OLM in PBMCs exposed to high D-glucose. That divergent behaviour, in fact, indicates that HG impacts differently on AT1R- and AT2R-mediated signal transduction pathways although our data do not allow any obvious explanation for that divergence. On a speculative basis, increased AT1Rs available for binding as a consequence of higher D-glucose concentrations [32] might potentiate the effect of OLM although the same should theoretically apply to AT2R stimulation given the sensitivity of that receptor subset to glucose concentrations [43]. The greater inhibitory effect of OLM might also relate to increased ANGII production in PBMCs grown in HG media [37, 38] although AT2R antagonism by PD 123, 329 per se was totally neutral on the procoagulant potential of PBMCs in our previous experience [14]. Thus, TF inhibition by C21 may merely represent the result of a pharmacological manipulation of physiologically silent binding sites activated by an agonist attaining concentrations at the receptor site far exceeding those achieved by ATII, the endogenous ligand [44]. Other mechanisms peculiar to AT1R blockers may also be at play including modulation of TLR4 expression and activity possibly independent of AT1R blockade [45] but this as well as all the above outlined possibilities are speculative and our data cannot provide any solid evidence in favour or against them.

**Conclusion**

This study confirms the stimulating property of HG on resting and activated procoagulant activity and demonstrate...
the obligatory role of NFKB in mediating the procoagulant effect of LPS in human PBMCs. In addition, we showed the neutral effect of HG on the TF-inhibiting effect of C21, a selective AT2R agonist, quite in contrast with the potentiating effect of OLM under the same experimental conditions, a divergent behaviour indicating that HG impacts differently on AT1R- and AT2R-mediated signal transduction pathways. However, further work is needed to understand the precise determinants of the phenomenon more precisely and the extent to which in-vitro data can be transferred to in-vivo conditions.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
CB carried out the PCA studies; VS carried out the TF antigen experiments; VC carried out the PCR gene expression; FF performed the statistical analysis; SC & TN drafted the manuscript; RZ & AC participated in design of the study; RP conceived the study and coordinated the research team. All authors read and approved the final manuscript.

Acknowledgments
Per Jansson (Vicore Pharma AB, Mintage Scientific AB, Gottebro, Sweden) and Dr Marco Chiapparelli (Dalichi Sankyo Italia SpA, Roma, Italy) supplied C21 and olmesartan respectively. The Authors are grateful to Ms Rosa Baviello, Biblioteca di Medicina e Chirurgia, Università di Pisa, for her help in bibliographic searches and articles retrieval.

Received: 25 November 2015 Accepted: 28 April 2016
Published online: 04 May 2016

References
1. Levi M, van der Poll T, Buller HR. Bidirectional relation between inflammation and coagulation. Circulation. 2004;109:2698–704.
2. Camerer E, Kolsta AB, Pyrdz H. Cell biology of tissue factor, the principal initiator of blood coagulation. Thromb Res. 1996;81:1–7.
3. Gilmore TD. Introduction to NF-kB players, pathways, perspectives. Oncogene. 2006;25:6680–4.
4. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev. 2006;86:747–803.
5. Brasier AR, Recinos 3rd A, Eledrisi MS. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol. 2002;22:1257–66.
6. Celi A, Del Fiorentino A, Cianchetti S, Pedrinelli R. Tissue factor modulation by angiotensin II: a clue to a better understanding of the cardiovascular effects of renin-angiotensin system blockade? Endocr Metab Immune Disord Drug Targets. 2008;8:308–13.
7. Dezzi B, Nielsen AH, Poulsen K. Identification of renin in resident alveolar macrophages and monocytes: HPLC and immunohistochemical studies. J Cell Sci. 1988;91:155–9.
8. Gomez RA, Norling LL, Wilfong N, Isakson P, Lynch KR, Hock R, Quensberry P. Leukocytes synthesize angiotensinogen. Hypertension. 1993;21:470–5.
9. Friedland J, Setton C, Silverstein E. Induction of angiotensin converting enzyme in human monocytes in culture. Biochem Biophys Res Commun. 1978;83:843–9.
10. Kitzazeni T, Richard C, Padgett MD, Armstrong ML, Tompkins PK, Heistad DD. Evidence that angiotensin II is present in human monocytes. Circulation. 1995;91:1129–34.
11. Kim MP, Zhou M, Wahl LM. Angiotensin II increases human monocyte matrix metalloproteinase-1 through the AT2 receptor and prostaglandin E2: implications for atherosclerotic plaque rupture. J Leukoc Biol. 2005;71:195–201.
12. Nestori E, Kushak R, Tsukurov O, Grabowski EF, Ingelliger JR. Role of the renin angiotensin system in TNF-alpha and Shiga-toxin-induced tissue factor expression. Pediatr Nephrol. 2008;23:221–31.
13. Balia C, Petroni S, Cordazzo C, Cianchetti S, Neri T, Cell A, Pedrinelli R. High glucose potentiates and renin-angiotensin blockade downregulates LPS-induced tissue factor expression in human mononuclear cells. Thromb Res. 2012;12:30552–6.
14. Balia C, Petroni S, Scalise V, Neri T, Carnicelli V, Cianchetti S, Zucchi R, Celli A, Pedrinelli R. Compound 21, a selective angiotensin II type 2 receptor agonist, downregulates lipopolysaccharide-stimulated tissue factor expression in human peripheral blood mononuclear cells. Blood Coagul Fibrinolysis. 2014;25:501–6.
15. Rompe F, Unger T, Steckelings UM. The angiotensin AT2 receptor in inflammation. Drug News Perspect. 2010;23:104–11.
16. Shamgunu N, Reddy MA, Guha M, Natarajan R. High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytes. Diabetes. 2003;52:1256–64.
17. Nishioka T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kareda Y, Yorek MA, Beebe D, Dates PJ, Hampe HS, Giardino I, Brownlie M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000;404:787–90.
18. Iwasaki Y, Kamayashi M, Asai M, Yoshida M, Nagawara T, Hashimoto K. High glucose alone, as well as in combination with proinflammatory cytokines, stimulates nuclear factor kappa-B-mediated transcription in hepatocytes in vitro. J Diabetes Complications. 2007;21:56–62.
19. Wan Y, Wallinder C, Piouiffe B, Beaudry H, Malmberg AK, Wu X, Johansson B, Holm M, Batoro M, Karlén A, Peterson T, Nyberg F, Fandriks L, Gallo-Payet N, Hallberg A. Alterman M. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem. 2004;47:5995–6008.
20. Beutler B, Hobe C, Du X, Ulevitch RJ. How we detect microbes and respond to them: the Toll-like receptors and their transducers. J Leukoc Biol. 2003;74:779–85.
21. Lee SH, Jung YM, Lee BH, Yun SJ, Yoo SE, Shin HS. Characterization of angiotensin II antagonism displayed by SK-1080, a novel nonpeptide AT1 receptor antagonist. J Cardiovasc Pharmacol. 1999;33:367–74.
22. Cent C, Chimenti D, Conti I, Neri T, Paggio G, Celli A. Monocyte/macrophage-derived microparticles up-regulate inflammatory mediator synthesis by human alveolar epithelial cells. J Immunol. 2006;177:1975–80.
23. Celli A, Pellegrini G, Lorenzet R, De Blasi A, Ready N, Furie BC, Furie B. P-selectin induces the expression of tissue factor by monocytes. Proc Natl Acad Sci U S A. 1994;91:8767–71.
24. Camera M, Brambilla F, Facchinetti L, Canzano P, Spirtos R, Rossetti L, Saccu C, Di Minno MN, Tremoli E. Tissue factor and atherosclerosis: not only vessel-wall derived TF, but also platelet-associated TF. J Thromb Res. 2012;12:279–84.
25. Garcia MG, Alaniz L, Lopes EC, Blanco G, Hajo S, Alvarez E. Inhibition of NF-kappaB activity by BAY 11–7082 increases apoptosis in multidrug resistant leukemic T-cell lines. Leuk Res. 2002;26:1425–34.
26. Blankley CJ, Hodges JK, Klutsko SR, Himmelsbach RJ, Chucholowski A, Connolly CJ, et al. Synthesis and structure-activity relationships of a novel series of non-peptide angiotensin II receptor binding inhibitors specific for the AT2 subtype. J Med Chem. 1991;34:3428–60.
27. Wu J, Yang X, Zhang YF, Zhou SF, Zhang R, Dong XQ, Fan JJ, Liu M, Yu XQ. Angiotensin II upregulates toll-like receptor 4 and enhances lipopolysaccharide-induced CD40 expression in rat peritoneal mesothelial cells. Inflamm Res. 2009;58:473–82.
28. De Batista PR, Palacios R, Martin A, Hernanz R, Medici CT, Silva MA, Rossii EM, Agudao A, Vasaio DV, Salaises M, Alonso MJ. Toll-like receptor 4 upregulation by angiotensin II contributes to hypertension and vascular dysfunction through reactive oxygen species production. PLoS One. 2014;9:e104020.
29. J Y, Liu J, Wang Z, Liu N. Angiotensin II induces inflammatory response partly via toll-like receptor 4-dependent signaling pathway in vascular smooth muscle cells. Cell Physiol Biochem. 2009;23:265–76.
30. Luo J, Sun J, Cai D. Effect of activating Toll-like receptor 4 on renin-angiotensin system in ST3-L1 adipose cells. Nan Fang Yi Ke Da Xue Xue Bao J South Med Univ. 2014;34:787–91.
31. De Fiorentino A, Cianchetti S, Cell A, Pedrinelli R, Aliskiren, a renin inhibitor, downregulates TNF-α-induced tissue factor expression in HUVECs. J Renin Angiotensin Aldosterone Syst. 2011;12:423–7.
32. Sodhi CP, Kanwar YS, Sahai A. Hypoxia and high glucose upregulate AT1 receptor expression and potentiate ANG II-induced proliferation in VSM cells. Am J Physiol Heart Circ Physiol. 2003;284:H8496–852.
33. Fernández-Real JM, Pickup JC. Innate immunity, insulin resistance and type 2 diabetes. Trends Endocrinol Metab. 2008;19:10–6.
34. Doki MF, Evangelides SA, Zhao L, Liang J. High glucose induces toll-like receptor 4 expression in human monocytes: mechanism of activation. Diabetes. 2008;57:3090–8.
35. Nareika A, Im YB, Game BA, State EH, Sanders JJ, London SD, Lopes-Virella MF, Huang Y. High glucose enhances lipopolysaccharide-stimulated CD14
expression in U937 mononuclear cells by increasing nuclear factor kappaB and AP-1 activities.

J Endocrinol. 2008;196:45–55.

36. Vidotti DB, Casarini DE, Cristovam PC, Leite CA, Schor N, Boim MA. High glucose concentration stimulates intracellular renin activity and angiotensin II generation in rat mesangial cells. Am J Physiol Renal Physiol. 2004;286:F1039–1045.

37. Lavrentyev EN, Estes AM, Malik KU. Mechanism of high glucose induced angiotensin II production in rat vascular smooth muscle cells. Circ Res. 2007;101:455–64.

38. Min Q, Bai YT, Jia G, Wu J, Xiang JZ. High glucose enhances angiotensin-II-mediated peroxisome proliferation-activated receptor-gamma inactivation in human coronary artery endothelial cells. Exp Mol Pathol. 2010;88:133–7.

39. Arun KH, Kaul CL, Ramara P. High glucose concentration augments angiotensin II mediated contraction via AT1 receptors in rat thoracic aorta. Pharmacol Res. 2004;50:561–8.

40. Amini F, Venema VJ, Wang X, Ju H, Venema RC, Marrero MB. Hyperglycemia enhances angiotensin II-induced janus-activated kinase/STAT signaling in vascular smooth muscle cells. J Biol Chem. 1999;274:32392–6.

41. Rompe F, Artuc M, Halberg A, Alterman M, Ströder K, Thöne-Reineke C, Reichenbach A, Schacherl J, Dahlfö B, Bader M, Aksenina N, Schwaninger M, Zuberbier T, Funke-Kaiser H, Schmidt C, Schunck WH, Unger T, Steckelings UM. Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB. Hypertension. 2010;55:924–31.

42. Menk M, Graw JA, von Haefen C, Sifringer M, Schwaiberger D, Unger T, Steckelings U, Spies CD. Stimulation of the Angiotensin II AT2 Receptor is Anti-inflammatory in Human Lipopolysaccharide-Activated Monocytic Cells. Inflammation. 2015;38:1690–9.

43. He M, Zhang L, Shao Y, Xue H, Zhou L, Wang XF, Yu C, Yao T, Lu LM. Angiotensin II type 2 receptor mediated angiotensin II and high glucose induced decrease in renal prorenin/renin receptor expression. Mol Cell Endocrinol. 2010;315:188–94.

44. Steckelings UM, Larhed M, Hallberg A, Widdop RE, Jones ES, Wallinder C, et al. Non-peptide AT2-receptor agonists. Curr Opin Pharmacol. 2011;11:187–92.

45. Larrayoz IM, Pang T, Benicky J, Pavel J, Sánchez-Lemus E, Saavedra JM. Candesartan reduces the innate immune response to lipopolysaccharide in human monocytes. J Hypertens. 2009;27:2365–76.